Investor Presentation Q1-Q3 2020
64
Investor presentation
First nine months of 2020
Scientific excellence ensures an innovative and competitive
pipeline with therapeutic solutions for severe conditions
Innovation in haemophilia
More than 35 years of innovation
EsperoctⓇ
Refixia®
NovoEight®
NovoThirteenⓇ
NovoSevenⓇ
Mim8
Concizumab
Non-invasive
therapy
Biopharm pipeline
Curative
therapy
Current
phases
2018
2019
2020
2021
Phase 3a
Phase 3a
Phase 1
EPI01 (SCD)
Phase 1/2
Concizumab
HA and HB1
Concizumab
HAWI/HBWI¹
Mim8
Phase 3
Somapacitan GHD
Phase 2
Somapacitan SGA
1986
Today
1 The convizumab phase 3 programme was resumed in August 2020.
Future
SCD: Sickle-cell disease; SGA: Short of gestational age; HwI: Haemophilia A or B patients with inhibitors; SGA: small for gestational age; GHD: Growth hormone deficiency
Novo NordiskⓇView entire presentation